James Michael Angelastro

InstitutionUniversity of California Davis
Address2221 VM3B
CA 95616
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Using Cell-Penetrant Peptides to Target ATF5 in Mouse Glioma Models
    NIH/NINDS R01NS083795Feb 15, 2014 - Jan 31, 2019
    Role: Principal Investigator
    Elimination of Carcinogen-Induced Tumor Stem Cells by ATF5 Loss of Function.
    NIH/NCI R21CA126924Jul 1, 2008 - Jun 30, 2011
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sears TK, Angelastro J. The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. Oncotarget. 2017 Oct 13; 8(48):84595-84609. PMID: 29137451.
      View in: PubMed
    2. Angelastro J. Targeting ATF5 in Cancer. Trends Cancer. 2017 Jul; 3(7):471-474. PMID: 28718401.
      View in: PubMed
    3. Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro J, Siegelin MD. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. Clin Cancer Res. 2016 Sep 15; 22(18):4698-711. PMID: 27126996; PMCID: PMC5026557 [Available on 09/15/17].
    4. Cates CC, Arias AD, Nakayama Wong LS, Lamé MW, Sidorov M, Cayanan G, Rowland DJ, Fung J, Karpel-Massler G, Siegelin MD, Greene LA, Angelastro J. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide. Oncotarget. 2016 Mar 15; 7(11):12718-30. PMID: 26863637; PMCID: PMC4914317.
    5. Napoli E, Ross-Inta C, Wong S, Hung C, Fujisawa Y, Sakaguchi D, Angelastro J, Omanska-Klusek A, Schoenfeld R, Giulivi C. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS One. 2012; 7(8):e42504. PMID: 22900024.
      View in: PubMed
    6. Lee HY, Angelastro J, Kenney AM, Mason CA, Greene LA. Reciprocal actions of ATF5 and Shh in proliferation of cerebellar granule neuron progenitor cells. Dev Neurobiol. 2012 Jun; 72(6):789-804. PMID: 22095825; PMCID: PMC3857133.
    7. Cunningham CL, Martínez Cerdeño V, Navarro Porras E, Prakash AN, Angelastro J, Willemsen R, Hagerman PJ, Pessah IN, Berman RF, Noctor SC. Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet. 2011 Jan 01; 20(1):64-79. PMID: 20935171; PMCID: PMC3000676.
    8. Angelastro J, Lamé MW. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res. 2010 Aug; 8(8):1105-15. PMID: 20663862; PMCID: PMC2923683.
    9. Li G, Li W, Angelastro J, Greene LA, Liu DX. Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. Mol Cancer Res. 2009 Jun; 7(6):933-43. PMID: 19531563; PMCID: PMC2880174.
    10. Greene LA, Lee HY, Angelastro J. The transcription factor ATF5: role in neurodevelopment and neural tumors. J Neurochem. 2009 Jan; 108(1):11-22. PMID: 19046351; PMCID: PMC2680418.
    11. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro J. Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol. 2007 Nov; 85(2):149-57. PMID: 17516028.
      View in: PubMed
    12. Monaco SE, Angelastro J, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer. 2007 May 01; 120(9):1883-90. PMID: 17266024.
      View in: PubMed
    13. Angelastro J, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN, Greene LA. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene. 2006 Feb 09; 25(6):907-16. PMID: 16170340.
      View in: PubMed
    14. Greene LA, Angelastro J. You can't go home again: transcriptionally driven alteration of cell signaling by NGF. Neurochem Res. 2005 Oct; 30(10):1347-52. PMID: 16341597.
      View in: PubMed
    15. Mason JL, Angelastro J, Ignatova TN, Kukekov VG, Lin G, Greene LA, Goldman JE. ATF5 regulates the proliferation and differentiation of oligodendrocytes. Mol Cell Neurosci. 2005 Jul; 29(3):372-80. PMID: 15950153.
      View in: PubMed
    16. Angelastro J, Mason JL, Ignatova TN, Kukekov VG, Stengren GB, Goldman JE, Greene LA. Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. J Neurosci. 2005 Apr 13; 25(15):3889-99. PMID: 15829641.
      View in: PubMed
    17. Ryu EJ, Angelastro J, Greene LA. Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis. 2005 Feb; 18(1):54-74. PMID: 15649696.
      View in: PubMed
    18. Angelastro J, Ignatova TN, Kukekov VG, Steindler DA, Stengren GB, Mendelsohn C, Greene LA. Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci. 2003 Jun 01; 23(11):4590-600. PMID: 12805299.
      View in: PubMed
    19. Ryu EJ, Harding HP, Angelastro J, Vitolo OV, Ron D, Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci. 2002 Dec 15; 22(24):10690-8. PMID: 12486162.
      View in: PubMed
    20. Töröcsik B, Angelastro J, Greene LA. The basic region and leucine zipper transcription factor MafK is a new nerve growth factor-responsive immediate early gene that regulates neurite outgrowth. J Neurosci. 2002 Oct 15; 22(20):8971-80. PMID: 12388604.
      View in: PubMed
    21. Angelastro J, Töröcsik B, Greene LA. Nerve growth factor selectively regulates expression of transcripts encoding ribosomal proteins. BMC Neurosci. 2002; 3:3. PMID: 11922865; PMCID: PMC100322.